Home > > Global Companion Animal Postoperative Pain Management Therapeutic Market Report
The Companion Animal Postoperative Pain Management Therapeutic market was valued at $312.8 Million in 2024, and is projected to reach $469.8 Million by 2031 growing at a CAGR of 6.04% from 2025 to 2031. NSAIDs segment is expected to be the highest contributor to this market, with $184.6 Million in 2024, and is anticipated to reach $270.7 Million by 2031, registering a CAGR of 5.68%. Opioids segment is anticipated to reach $63.8 Million by 2031 with the highest CAGR of 8.66%. NSAIDs and Anesthetics segments collectively expected to account for about 87.1% share of the Companion Animal Postoperative Pain Management Therapeutic market in 2024, with the former constituting around 59.0% share. Opioids and NSAIDs segments are expected to witness significant growth rates at a CAGR of 8.66% and 5.68% respectively, during the forecast period. Presently, share of these two segments is estimated to be around 70.5% in the overall Companion Animal Postoperative Pain Management Therapeutic market in 2024, and is anticipated to reach 71.2% by 2031.-------------Product NSAIDs Anesthetics Opioids Other Products Animal Type Canine Feline BY REGION North America U.s. Canada Europe Germany U.k. France Italy Spain Rest of Europe Asia China Japan South Korea India Indonesia Rest of Asia Middle East & Africa Brazil Mexico South Africa Australia Rest of MENA